1. Home
  2. SEED vs VTGN Comparison

SEED vs VTGN Comparison

Compare SEED & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Origin Agritech Limited

SEED

Origin Agritech Limited

SELL

Current Price

$0.69

Market Cap

8.5M

ML Signal

SELL

Logo VistaGen Therapeutics Inc.

VTGN

VistaGen Therapeutics Inc.

SELL

Current Price

$0.19

Market Cap

9.5M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
SEED
VTGN
Founded
1997
1998
Country
China
United States
Employees
N/A
N/A
Industry
Farming/Seeds/Milling
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.5M
9.5M
IPO Year
2005
2014

Fundamental Metrics

Financial Performance
Metric
SEED
VTGN
Price
$0.69
$0.19
Analyst Decision
Hold
Analyst Count
0
4
Target Price
N/A
★ $1.00
AVG Volume (30 Days)
15.3K
★ 707.6K
Earning Date
05-21-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
★ N/A
N/A
Revenue This Year
N/A
$33.96
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.65
$0.17
52 Week High
$1.73
$5.14

Technical Indicators

Market Signals
Indicator
SEED
VTGN
Relative Strength Index (RSI) 41.77 45.36
Support Level $0.67 $0.17
Resistance Level $1.07 $0.32
Average True Range (ATR) 0.05 0.01
MACD -0.00 0.00
Stochastic Oscillator 19.11 72.12

Price Performance

Historical Comparison
SEED
VTGN

About SEED Origin Agritech Limited

Origin Agritech Ltd is a Chinese agricultural technology company operating in the PRC including seed research and development activities featured in crop seed breeding and genetic improvement. The company's phytase corn was the first transgenic corn to receive the Bio-Safety Certificate from China's Ministry of Agriculture. Origin has established a robust biotechnology seed pipeline including products with glyphosate tolerance and pest resistance (Bt) traits.

About VTGN VistaGen Therapeutics Inc.

Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.

Share on Social Networks: